UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Archives

2024
- September
- August
- July
- June
- May
- April
- March
- February
- January
2023
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2022
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2021
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2020
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2019
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
2018
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January

Jan

30 Collaboration with Duke University Focuses on Health Equity for Adolescents in Uganda

Read More Share:

|

Jan

20 Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Read More Share:

|

Jan

18 Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Read More Share:

|

Jan

17 5 U.S. Organizations Receive Support from UCB Community Health Fund

Read More Share:

|

Jan

13 Patient-first: UCB is there to listen to patients, to not only learn more about them but also from them

Read More Share:

|

Jan

06 UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Read More Share:

|

Categories

Archives

Jan

30

Collaboration with Duke University Focuses on Health Equity for Adolescents in Uganda

Jan

20

Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Jan

17

5 U.S. Organizations Receive Support from UCB Community Health Fund

Jan

13

Patient-first: UCB is there to listen to patients, to not only learn more about them but also from them

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Choose Country

UCB in the U.S.

Patients

Innovation

Sustainability

Newsroom

Contact

Categories

Archives

Jan

30

Collaboration with Duke University Focuses on Health Equity for Adolescents in Uganda

Jan

20

Employee Spotlight: Ian Crassweller – Leading and Evolving Through Change

Jan

18

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

Jan

17

5 U.S. Organizations Receive Support from UCB Community Health Fund

Jan

13

Patient-first: UCB is there to listen to patients, to not only learn more about them but also from them

Jan

06

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Sustainability

Newsroom

Contact